Live from San Francisco, we compiled all the biggest news from Microsoft's annual developer conference. This is how Microsoft sees the future of AI computing. Microsoft Build is officially over, but ...

shows the logo of Microsoft displayed on the facade of the company France headquarters in Issy-les-Moulineaux, on the outskirts of Paris, on April 24, 2026. Martin LELIEVRE/Getty Images Microsoft ...

I wore the world's first HDR10 smart glasses TCL's new E Ink tablet beats the Remarkable and Kindle Anker's new charger is one of the most unique I've ever seen Best laptop cooling pads Best flip ...

Mustafa Suleyman, executive vice president and CEO, Microsoft AI, and Mayo Clinic CEO Gianrico Farrugia at Microsoft Build 2026 in San Francisco. (Photo by Dan DeLong) Mayo Clinic plans to develop and ...

Microsoft is so keen to help you deploy AI agents, it's building its own version of OpenClaw — and a new agentic OS based on Android rather than Windows. CEO Satya Nadella doubled down on AI agents ...

Homeland Security Secretary Markwayne Mullin is defending conditions at the Delaney Hall ICE detention facility in Newark, New Jersey. The center has been the site of ongoing protests that have at ...

Microsoft used its Build 2026 developer conference on Tuesday to announce a new family of in-house AI models, alongside a slew of other news. The announcements, delivered during CEO Satya Nadella's ...

Build will include a Copilot super app, a new reasoning AI model, and lots of Windows improvements. Build will include a Copilot super app, a new reasoning AI model, and lots of Windows improvements.

Microsoft's developer-focused Build conference is usually heavy on technical details, but it's still the best way to get a sneak peek into what the company has in store for your Windows PC. I'll be on ...

MADISON COUNTY, Ala. (WHNT) — Multiple fire departments responded to a large fire at a storage building in the 100 block of Teresa Drive on Sunday. The Harvest Volunteer Fire Department said it joined ...

At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...